AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18007263
Drug: Enteral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral supplement
Trial: 16420512
Drug: 48-week peginterferon-alpha-2b
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Trial: 16420512
Drug: 24-week peginterferon-alpha-2b
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Trial: 12830603
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter plus titrated oral misoprostol solution
Trial: 12830603
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral misoprostol solution alone
Trial: 1486157
Drug: Delayed-release indomethacin
RxNorm normalized name: indomethacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release indomethacin (Eudragit L formulation)
Trial: 27731828
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 50 mg test (F4) tablet formulation
Trial: 24815497
Drug: Indomethacin (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (nonselective COX inhibitor)
Trial: 24815497
Drug: Celebrex (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celebrex (selective COX-2 inhibitor)
Trial: 10403615
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sinitrodil
Trial: 10403615
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sinitrodil
Trial: 10403615
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg sinitrodil
Trial: 31570246
Drug: Postoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative chemoradiation therapy (CRT)
Trial: 31570246
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy alone
Trial: 23968769
Drug: rWN/DEN4Δ30 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rWN/DEN4Δ30 vaccine at 10³ PFU
Trial: 23968769
Drug: rWN/DEN4Δ30 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rWN/DEN4Δ30 vaccine at 10⁴ PFU
Trial: 23968769
Drug: rWN/DEN4Δ30 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rWN/DEN4Δ30 vaccine at 10⁵ PFU
Trial: 23968769
Drug: rWN/DEN4Δ30 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rWN/DEN4Δ30 vaccine at 10⁵ PFU (second dose)
Trial: 22068922
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch (17.4 mg/24 h)
Trial: 22068922
Drug: Rivastigmine capsule
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsule (12 mg/day)
Trial: 15668708
Drug: GT after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT after chemotherapy
Trial: 8750368
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous lamivudine (administered over 1 hour)
Trial: 8750368
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral lamivudine (1 mg/mL)
Trial: 8750368
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet
Trial: 8750368
Drug: All oral
RxNorm normalized name: Exall Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All oral formulations (oral solution, capsule, tablet)
Trial: 27935458
Drug: Group session
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group session of hypnosis with a hypnotic induction (n = 84)
Trial: 27935458
Drug: No-induction group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-induction group receiving identical suggestions without a hypnotic induction (n = 83)
Trial: 23359433
Drug: Adjuvant lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO)
Trial: 20012308
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg daily for 6 months
Trial: 17531764
Drug: HPV-16/18 L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 L1 VLP AS04 vaccine administered at months 0, 1, and 6
Trial: 17531764
Drug: HPV-16/18 L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 L1 VLP AS04 vaccine
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/drospirenone)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/cyproterone)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/desogestrel)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/gestodene)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/chlormadinone)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/levonorgestrel)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/norethindrone)
Trial: 15663340
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (ethinylestradiol/norgestimate)
Trial: 11680569
Drug: Thymoglobulin (rabbit
RxNorm normalized name: Thymoglobulin (rabbit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (rabbit anti‐thymocyte globulin), 1.5 mg/kg/day for 6‐14 days
Trial: 9477711
Drug: Consolidated Standards
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidated Standards for Preparation of Controlled Clinical Trials (CONSORT) checklist
Trial: 7861706
Drug: Before angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before angiotensin infusion
Trial: 7861706
Drug: During angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During angiotensin infusion
Trial: 26178501
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (stable blood glucose at 6.1‐8.3 mmol/L)
Trial: 23201367
Drug: Strong placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strong placebo treatment
Trial: 23201367
Drug: Weak placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weak placebo treatment
Trial: 23201367
Drug: Placebo treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatments (both strong and weak)
Trial: 21694454
Drug: Transdermal 17‐β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17‐β estradiol (unopposed and opposed with medroxyprogesterone) for 12 months
Trial: 16148997
Drug: Multiple cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple cancer group (MCG)
Trial: 11822980
Drug: Phytoestrogens and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogens and selective estrogen receptor modulators
Trial: 9442338
Drug: (-)-3PPP, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-3PPP, 300 mg B.I.D. in early efficacy study
Trial: 2643894
Drug: Droperidol, 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol, 0.075 mg/kg
Trial: 2643894
Drug: Lidocaine, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine, 1.5 mg/kg
Trial: 2643894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lidocaine, 1.5 mg/kg and droperidol, 0.025 mg/kg
Trial: 29949407
Drug: Acute intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intravenous hypertonic saline infusion (HSI)
Trial: 27060853
Drug: Sertraline/Olanzapine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline/Olanzapine combination treatment
Trial: 23363721
Drug: Domestic hydrochloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic hydrochloric trimetazidine capsules
Trial: 23363721
Drug: Imported hydrochloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported hydrochloric trimetazidine tablets
Trial: 8002198
Drug: Survey questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey questionnaire utilizing a 30-day recall period with the combination of cough, fast breathing or shortness of breath, and fever.
Trial: 30033645
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root supplement (60 mg of active gingerols/day, four capsules)
Trial: 25801058
Drug: Tong Xin
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tong Xin Luo + Simvastatin 20 mg (after 7 days of TCM)
Trial: 25801058
Drug: Nao Xin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nao Xin Tong + Simvastatin 20 mg (after 7 days of TCM)
Trial: 25801058
Drug: Guan Mai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guan Mai Ning + Simvastatin 20 mg (after 7 days of TCM)
Trial: 25801058
Drug: Yin Xing
RxNorm normalized name: ALLOGENIC ADIPOSE DERIVED MESENCHYMAL STEM CELLS (MSCS) EXOSOMES 15 mg in 3 mL TOPICAL POWDER, FOR SOLUTION [XINGHUI Cell Exosome]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yin Xing Ye + Simvastatin 20 mg (after 7 days of TCM)
Trial: 19145455
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol intake (3.3 g/day)
Trial: 17925563
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2) plus gemcitabine (1,000 mg/m2)
Trial: 17925563
Drug: Cisplatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (40 mg/m2) plus vinorelbine (25 mg/m2)
Trial: 14963675
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg cerivastatin
Trial: 11712610
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation combined with soft tissue therapy
Trial: 30213365
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine added to PMDI (Group A)
Trial: 30213365
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg morphine added to spinal anesthesia (Group B)
Trial: 30213365
Drug: No morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No morphine added (Group C)
Trial: 21277694
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to protocol specified radiation therapy guidelines (PP)
Trial: 21277694
Drug: Non-adherence to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherence to protocol specified radiation therapy guidelines (<PP)
Trial: 21277694
Drug: Gemcitabine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine treatment with adherence to RT guidelines (PP)
Trial: 18307372
Drug: Imipenem administration
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem administration in healthy volunteers
Trial: 18307372
Drug: Imipenem administration
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem administration in critical care patients
Trial: 16575033
Drug: Remifentanil (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Group R) - basal infusion of 0.02-0.04 microg x kg(‐1) x min(‐1) with self-administered bolus doses of 0.3 microg x kg(‐1) i.v. every minute as required.
Trial: 16575033
Drug: Propofol (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (Group P) - initial plasma target concentration set at 3-4 microg x mL(‐1).
Trial: 12679757
Drug: Oral glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin
Trial: 11294060
Drug: Amisulpride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (300 mg daily)
Trial: 11294060
Drug: Amisulpride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400 to 800 mg/day, up to 1,200 mg/day)
Trial: 2866133
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg at bedtime
Trial: 2866133
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg b.i.d.
Trial: 2866133
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg b.i.d.
Trial: 25378974
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pravastatin
Trial: 22722481
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of tegafur suppositories (group A)
Trial: 22722481
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative treatment (group B)
Trial: 17590291
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black cohosh alone (monotherapy)
Trial: 17590291
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black cohosh in combination with St. John's wort (combination therapy)
Trial: 17590291
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (Black cohosh alone and combination therapy)
Trial: 8527271
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral ketoprofen
Trial: 8527271
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral ketoprofen
Trial: 8527271
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg i.v. ketoprofen
Trial: 8527271
Drug: R-ketoprofen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-ketoprofen (oral administration)
Trial: 31264282
Drug: Extra-fine particle
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate (mean dose 355µg) after switching from fine particle ICS (mean dose 710µg)
Trial: 27868321
Drug: sacubitril/valsartan 97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 97/103 mg b.i.d.
Trial: 27868321
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg b.i.d.
Trial: 12764905
Drug: Shengfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengfu Injection (SFI) plus chemotherapy
Trial: 11054326
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide sustained drug delivery device
Trial: 12206030
Drug: Colgate Optimized
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Optimized Stannous Fluoride (COSF) dentifrice, containing 0.454% stannous fluoride, stannous chloride, polyphosphate, and citrate in a silica base, used twice daily for 6 months.
Trial: 31511069
Drug: Atezolizumab (anti-PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (anti-PD-L1 antibody) treatment
Trial: 18775942
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) in addition to standard care
Trial: 9149190
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation (one bottle of magnesium citrate and two 'Dulcolax' tablets)
Trial: 9149190
Drug: Enema preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema preparation (two Fleet's enemas)
Trial: 8196323
Drug: gelatin aiconol
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin aiconol in capsules (Group 4, 40 subjects)
Trial: 29182212
Drug: Self-etch approach
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-etch approach using a Universal dentine bonding agent (Scotchbond Universal)
Trial: 21645332
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg perhexiline maleate
Trial: 19546692
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 0.05 mg/kg
Trial: 19546692
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 0.2 mg/kg
Trial: 19546692
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 0.4 mg/kg
Trial: 16988202
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg administered as a 15-minute 50-mL intravenous infusion
Trial: 16988202
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg administered as a 30-second 5-mL infusion
Trial: 30121611
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support system plus automated daily supportive/reminder text messages
Trial: 30121611
Drug: Automated daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated daily supportive/reminder text messages alone
Trial: 30121611
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual follow-up care
Trial: 23314695
Drug: IgM-enriched immunoglobulin
RxNorm normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched immunoglobulin (5 ml/kg via 8 h IV-infusion for three consecutive days)
Trial: 23314695
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml/kg via 8 h IV-infusion for three consecutive days)
Trial: 19082406
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of 0.5% hyperbaric bupivacaine with 2.5 microg of sufentanil and 30 microg of clonidine (CLON/HYPER Group)
Trial: 19082406
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of 0.5% isobaric bupivacaine with 2.5 microg of sufentanil and 30 microg of clonidine (CLON/ISO Group)
Trial: 16210048
Drug: IVL745 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVL745 (20 mg, twice daily for 7 days)
Trial: 2473515
Drug: Colloid cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid cardioplegic solution (35 g dextran 40 added to St Thomas II solution)
Trial: 2473515
Drug: Standard crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard crystalloid cardioplegic solution
Trial: 30656460
Drug: Prospective ECG-triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective ECG-triggered sequential protocol (group 1)
Trial: 25008877
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment (200 IU/(kg.d) by intravenous infusion for 7 days)
Trial: 21859516
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention consisting of joint meal preparation and activities for children and parents, administered once weekly by a nutrition expert for 6 months.
Trial: 15842140
Drug: Shennong No.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shennong No. 33 (SN33) in addition to comprehensive therapy